ABU DHABI, UNITED ARAB EMIRATES: Burjeel Holdings, one of the largest healthcare service providers in the Middle East and North Africa (MENA) region, has announced a partnership with OncoHelix Inc. to establish a cutting-edge laboratory in Abu Dhabi.
The lab will provide advanced molecular genetics, cellular, and immunological profile testing to patients in the UAE. This initiative will help bring personalized medicine to clinics and hospitals in the UAE.
The new laboratory will be divided into two arms. The first arm will focus on offering groundbreaking molecular genetics and immunological profiling tests to assist oncologists and physicians in the diagnosis, risk stratification, and tailored treatment for patients with cancer, genetic diseases, or immune disorders.
The second arm will expand Burjeel Holdings’ existing translational research program and analyze cancer patients’ genomic and immune signatures to develop innovative approaches for diagnosis and treatment.
OncoHelix, based in Western Canada, is a leading clinical diagnostics and translational research company. Its scientists and clinicians have an impeccable record in translational research, with over 350 publications in major scientific journals.
Their precision oncology and immunology pipelines have shown impactful results in improving clinical outcomes for cancer patients and transplant recipients.
Burjeel Holdings operates a network of 61 assets, including 16 hospitals and 23 medical centers, as well as pharmacies and other allied services. Its Laboratory Services arm, coLAB, operates a network of 12 internationally accredited laboratories including 4 labs accredited by the College of American Pathologists.
The partnership between OncoHelix and Burjeel Holdings represents an important step forward in expanding clinical diagnostics and translational research, as well as improving healthcare outcomes for patients in the UAE.
The laboratory is expected to begin operations by the end of this year, and it will be capable of facilitating the requirements of the region’s hospitals.
John Sunil, CEO of Burjeel Holdings, said that through this agreement, the company hopes to solidify its position as a leading provider of complex care in the UAE and increase its capabilities to serve the country’s growing medical tourism market. He added that collaborations like these will benefit the UAE as it transforms into a global leader in healthcare.
Dr. Faisal Khan, CEO of OncoHelix and Associate Professor at the University of Calgary, said that the partnership with Burjeel Holdings will aid in the early and accurate diagnosis of malignancies and immunological disorders, as well as pave the road for newer treatment options guided by disease-specific molecular signatures.
The translational research program will investigate the somatic and germline variant landscapes of cancer patients, as well as the immune profile patterns of transplant recipients and donors from the region, to lead the development of precision medicine-based treatment methods.
Cyclyx commissions new plastics laboratory in New Hampshire, USA
Leave a Reply